Updated version of my 'Genome assembly: then and now' talk is now available

This is a presentation that I have probably given five times now. Originally, the main focus of the talk was purely about the Assemblathon 2 paper, with some thoughts about how the field of genome assembly has changed since the days of Sanger-only sequencing.

Over time, I've increasingly downplayed the Assemblathon 2 content of the talk, and made way for updates relating to the latest developments in genome sequencing and assembly. To that end, I've decided to start adding version numbers to this talk to help make it easier to distinguish between different versions.

So here is version 1.2 of my talk, presented below with and without notes (my talks are very visual, so I have embedded notes to try to capture what I talk about for each slide). Don't be put off by the high slide count (many of these just reflect animated steps).

Without notes…

With notes (probably need to go full-screen to be able to clearly read these)…

Too many genome assemblers to keep track of? Nucleotid.es to the rescue!

Yesterday, I presented an updated version of my 'Genome Assembly: Then and Now' talk. I'll try to post the full set of slides (with notes) later today on Slideshare. But I thought I'd share just one of the new slides from the talk; here are six papers that describe new genome assembly tools…

Read More

New option to subscribe to this blog via email

Shamelessly borrowing this idea from Matt Gemmell's excellent blog, I thought I'd offer the chance to subscribe to my infrequent ramblings via email. If you enter your email address below, you can receive a weekly email (sent on Friday afternoons) with all of my posts for that week.

Your email address will only be used for the purpose of receiving my blog content and will not be shared with anyone else. Each email will offer a simple link by which to unsubscribe.

Some sage advice on avoiding confusing names for bioinformatics tools

SAGE is a molecular technique used to investigate the mRNA population from a chosen sample. It stands for Serial Analysis of Gene Expression and was first described back in 1995. The technique spawned spin-offs such as LongSAGE, RL-SAGE (Really Long SAGE), and SuperSAGE.

Although this technique has largely been superseded by other methods (such as RNA-Seq), it is still widely referenced (over 1,300 publications from 2013 mention this technique).

Fast-forward to the present day and I note that a new tool has just been published in the journal BMC Bioinformatics:

SAGE: String-overlap Assembly of GEnomes

As long as you query your favorite web search engine for some combination of 'SAGE' and 'genome assembly' you will probably find this tool and not end up on one of the half a million pages that talk about the other SAGE. I'm still not sure whether it is a bit risky giving a new tool the same name as such an established molecular technique.

All of this means that there is the potential for a certain company to use the aforementioned molecular technique to help annotate the output of the aforementioned computational technique, and apply both of these techniques to data from a certain plant. This could give you the world's first SAGE, SAGE, SAGE, sage genome!

Understanding CEGMA output: complete vs partial

On Friday I posted a reply to a thread on SEQanswers about CEGMA. I thought I'd include a modified version of that response here as it is an issue that gets raised fairly frequently. It concerns the 'complete' and 'partial' results that CEGMA includes in the final output file that it generates (typically called 'output.completeness_report'). Here were the two questions that were posted:

1) If a partial score is higher than a complete score then does this indicate that the assembly is fragmented?

2) Also, should the partial score be lower than the complete score in an ideal situation?

Remember, these are not scores per se. Both of these figures describe a number of core eukaryotic genes (CEGs) that the CEGMA pipeline predicts to be present in the input assembly file. The 'complete' set  refers to those gene predictions which CEGMA classes as 'full-length'. Note that even if CEGMA says something is 'complete' there is still the possibility that parts of the protein is missing.

This is because CEGMA is taking each CEG that it has predicted and aligns the protein sequence of that CEG to the HMM profile generated from the corresponding core gene family (made up of six proteins from Schizosacchromyces pombe, Saccharomyces cerevisiaeCaenorhabditis elegans, Drosophila melanogasterArabidopsis thaliana, and Homo sapiens). As I recall from memory, if the alignment spans more than 70% of the protein profile the CEG is considered to be 'complete'. This 70% threshold is an arbitrary cut-off, but seems to work well in finding genuine orthologs of CEGs.

Somewhat confusingly, although we consider 'partial' matches to be those below 70% (but above some unspecified minimum score), the output in output.completeness_report uses 'partial' to include both 'complete' and 'partial' matches. So the number of partial matches will always be at least as high as the number of complete matches.

You should look at both results. If you don't have 248 core genes 'completely' present, the next thing is look at how many additional partial matches there are. If you have a result like 200/240 (i.e. 200 complete CEGs and 40 additional partial matches) then this at least suggests that most of the core gene set is present in your assembly, but some may be split across contigs or missing from the assembly. Remember, CEGMA only looks for genes that are located inside individual contigs or scaffolds. Theoretically, you could have an assembly that splits every gene across contigs which might lead to a 'complete' result of zero, and a partial result of '248'.

From looking at results of many different runs of CEGMA, it is common to see something like 90–95% of core gene present in the 'complete' category, and another 1–5% present as partial genes (for good assemblies at least). I have also seen one case where the results were 157/223. This is more unusual, suggesting that a relatively large number (27%) of the core genes were present as fragments. This might simply reflect lots of short contigs/scaffolds in the assembly. In contrast to this, one of the best results that I have seen is 245/248. It is rare to see all core genes present, even when you allow for partial matches.

Below is a chart that shows the results from 50 runs of CEGMA against different assemblies. The x-axis shows the percentage of 248 CEGs that were completely present, and the y-axis shows the percentage of CEGs that were only partially present.

Is yours bigger than mine? Big data revisited

Google Scholar lists 2,090 publications that contain the phrase 'big data' in their title. And that's just from the first 9 months of 2014! The titles of these articles reflect the interest/concern/fear in this increasingly popular topic:

One paper, Managing Big Data for Scientific Visualization, starts out by identifying a common challenge of working with 'big data':

Many areas of endeavor have problems with big data…while engineering and scientific visualization have also faced the problem for some time, solutions are less well developed, and common techniques are less well understood

They then go on to discuss some of the problems of storing 'big data', one of which is listed as:

Data too big for local disk — clearly, not only do some of these data objects not fit in main memory, but they do not even fit on local disk on most workstations. In fact, the largest CFD study of which we are aware is 650 gigabytes, which would not fit on centralized storage at most installations!

Wait, what!?! 650 GB is too large for storage? Oh yes, that's right. I forgot to mention that this paper is from 1997. My point is that 'big data' has been a problem for some time now and will no doubt continue to be a problem.

I understand that having a simple, user-friendly, label like 'big data' helps with the discussion, but it remains such an ambiguous, and highly relative term. It's relative because whether you deem something to be 'big data' or not might depend heavily on the size of your storage media and/or the speed of your networking infrastructure. It's also relative in terms of your field of study; a typical set of 'big data' in astrophysics might be much bigger than a typical set of 'big data' in genomics.

Maybe it would help to use big dataTM when talking about any data that you like to think of as big, and then use BIG data for those situations where your future data acquisition plans cause your sys admin to have sleepless nights.

The problem with posters at academic conferences

I recently attended the Genome Science: Biology, Technology, and Bioinformatics meeting in the UK, where I presented a poster. As I was walking around, looking at other people's posters, I was reminded of the common problem that occurs with many academic posters. Here are some pseudo-anonomous examples to show what I mean (click images to enlarge):

The problem here is not with the total amount of text — though that can sometimes be an issue — but with the width of the text. These posters are 84 cm (33 inches) wide, and it is not ideal to create text blocks that span the entire width of the poster. The reasons behind this are the same reasons why you never see newspapers display text like this…we are not very good at reading information in this manner.

To quote from Lynch & Horton's Web Style Guide; specifically the section on Page Width and Line Length:

The ideal line length for text layout is based on the physiology of the human eye. The area of the retina used for tasks requiring high visual acuity is called the macula. The macula is small, typically less than 15 percent of the area of the retina. At normal reading distances the arc of the visual field covered by the macula is only a few inches wide—about the width of a well-designed column of text, or about twelve words per line. Research shows that reading slows as line lengths begin to exceed the ideal width, because the reader then needs to use the muscles of the eye or neck to track from the end of one line to the beginning of the next line. If the eye must traverse great distances on a page, the reader must hunt for the beginning of the next line.

In contrast to the above examples, there were a couple of posters at the #UKGS2014 meeting that I thought were beautifully displayed. Bright, colorful, clearly laid out, not too much text, and good use of big fonts. Congratulations to Warry Owen et al. and Karim Gharbi et al. for your poster presentation prowess!

When is a citation not a citation?

Today I received a notification from Google Scholar that one of my papers had been cited. I often have a quick look at such papers to see how our work is being referenced. The article in question was from the Proceedings of the 3rd Annual Symposium on Biological Data Visualization: Data Analysis and Redesign Contests:

FixingTIM: interactive exploration of sequence and structural data to identify functional mutations in protein families

The paper describes a tool that helps "identify protein mutations across a family of structural models and to help discover the effect of these mutations on protein function". I was a bit surprised by this because this isn't a topic that I've published on. So I looked to see what paper of mine was being cited and how it was being cited. Here is the relevant sentence from the background section of the paper:

To improve the exploration process, many efforts have been made, from folding the sequences through classification [1,2], to tools for 3D view exploration [3] and to web-based applications which present large amounts of information to the users [4].

Citation number 2 is the paper on which I am a co-author:

  • Chen N, Harris TW, Antoshechkin I, Bastiani C, Bieri T, Blasiar D, Bradnam K, Canaran P, Chan J, Chen C, Chen WJ, Cunningham F, Davis P, Kenny E, Kishore R, Lawson D, Lee R, Muller H, Nakamura C, Pai S, Ozersky P, Petcherski A, Rogers A, Sabo A, Schwarz EM, Van Auken K, Wang Q, Durbin R, Spieth J, Sternberg PW, Stein LD: Wormbase: A comprehensive data resource for Caenorhabditis biology and genomics. Nucleic Acids Res 2005, 33(1):383-389.

The cited paper simply describes the WormBase database and includes only a passing reference to the fact that WormBase contains some links to protein structures (when known), but that's about it. The WormBase paper doesn't mention 'folding' or 'classification' anywhere, which makes it seem a really odd choice of paper to be cited. It makes me wonder how many other papers end up gaining seemingly spurious citations like this one.

Thoughts on the supply of bioinformatics services and training in the UK

I am currently at the 2014 UK Genome Sciences meeting (hashtag #UKGS2014). It has been a long time since I have been at a UK science conference and it has been good to meet old colleagues and acquaintances who I have known from various stages of my career.

From informal chats with various people, it seems that UK universities are tackling their bioinformatics needs in different ways. Some have specialized facilities that try to meet the bioinformatics need from local users (and potentially from those further afield). E.g. the University of Surrey has a Bioinformatics Core Facility, Newcastle University has a Bioinformatics Support Unit, and here at Oxford there is the Computational Biology Research Group.

These examples represent core facilities with dedicated staff. An alternative approach is to bring together — physically or virtually — existing bioinformatics talent, with a view that they will be able to help others. This is the strategy taken by the new Bioinformatics Hub at the University of Sheffield, which brings together six talented folk who are based in different departments. The success of strategies like this may heavily depend on having enough skilled bioinformatics faculty who also have enough time to help others.

Other universities seem to lack any central pooling of bioinformatics expertise, and instead rely on people doing bioinformatics themselves or outsourcing it to places like TGAC. The former approach (doing it yourself) will be fine for some people, particularly those who are comfortable learning new computational skills themselves, but this will not be a good fit for everyone. 

If you are not outsourcing your bioinformatics and you don't have the necessary skills yourself, then the other approach is to attend one or more training courses. Three places that seem to be leading the field for bioinformatics training are TGACCGAT, and Edinburgh Genomics…and all three have a heavy presence at this conference.

Depending on your definition, bioinformatics has been around — as either a recognized skill set, or a field of study — since the early 1990s. The number of people who might consider themselves a bioinformatician has probably grown exponentially since then. Likewise, the demand for skilled bioinformaticians, or for facilities that offer bioinformatics services and training, continues to grow. Clearly, there are different ways of meeting this demand.

The current diversity of approaches to bioinformatics services and training presumably is a reflection on the local supply of, and demand for, such services. If you are about to join a new university, and if you plan on needing some bioinformatics help at some point, it may be useful to first find out more about that university's bioinformatics strategy.

My poster for the UK Genome Sciences meeting is about a new version of our IMEter software

One of the many projects I am involved with looks at Intron-mediated enhancement (IME) of gene expression. Our collaboration with Alan Rose at UC Davis has been a fruitful one, and has led to the development of computational tools that can predict how much an intron might enhance expression.

The initial version of what we called 'the IMEter' was published in 2008 and an improved v2.0 version was published in 2011. The online version of this software only lets you test Arabidopsis introns…not so useful when there are now so many different sequenced plant genomes.

We addressed this limitation in a new — as yet unpublished — v2.1 version which is available online. IMEter v2.1 can now test the expression enhancing ability of introns from 34 different plant species.

The new IMEter is the subject of my poster at the forthcoming UK Genome Sciences meeting in Oxford. The poster, available below via Figshare, explains a little more about how the new version of the IMEter came about. It also discusses some of the problems that arise in trying to adapt a software tool from working with one, very well annotated, genome, to working with many different genomes of varying quality.